Kangchen Pharmaceutical's KC1036 entered Phase Ib/II clinical study for the treatment of advanced digestive system tumors

On February 23, Kangchen Pharmaceutical issued an announcement saying that recently, Kangchen Pharmaceutical's "Phase Ib/II clinical study plan to evaluate the efficacy and safety of KC1036 in the treatment of advanced recurrent or metastatic digestive system tumors" was published in the Chinese Academy of Medical Sciences.

Brief introduction of KC1036:

KC1036 Tablets is a class 1 innovative drug of chemical drugs independently developed by the company that has not been marketed at home and abroad, and is intended to be used for the treatment of solid tumors and hematological tumors

The company obtained the "Clinical Trial Notice" for KC1036 tablets approved and issued by the State Drug Administration in January 2020; An open-label, dose-escalating Phase I clinical study on the safety, tolerability and pharmacokinetics of the company”, according to the clinical trial data results disclosed by the company in the designated media in September 2021, KC1036 single drug has a good safety profile and tolerability, showed prominent anti-tumor activity in patients with advanced solid tumors tested, and the research is currently being actively carried out; at the same time, based on the clinical research carried out in the early stage, the company decided to cooperate with the Cancer Hospital of the Chinese Academy of Medical Sciences.